ORIC Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ORIC Nasdaq 2834 www.oricpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ORIC Pharmaceuticals, Inc.

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - Aug 3rd, 2026 2:05 pm
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Jul 20th, 2026 6:30 am
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer - Jul 14th, 2026 2:05 pm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Jul 2nd, 2026 2:30 pm
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - May 27th, 2026 2:05 pm
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - May 17th, 2026 7:23 am
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - May 4th, 2026 2:05 pm
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Apr 17th, 2026 2:05 pm
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data - Apr 6th, 2026 3:08 am
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - Apr 2nd, 2026 6:20 am
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Apr 2nd, 2026 2:13 am
Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges - Apr 1st, 2026 2:16 pm
Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened - Apr 1st, 2026 7:16 am
Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial - Mar 31st, 2026 5:07 pm
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile - Mar 31st, 2026 2:05 pm
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC - Mar 27th, 2026 6:30 am
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. - Mar 19th, 2026 1:23 pm
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting - Mar 17th, 2026 3:01 pm
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns - Mar 13th, 2026 3:11 am
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Recent Share Price Volatility - Mar 12th, 2026 8:13 pm